现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
24期
3557-3559
,共3页
李小平%张晓伟%郭伟剑%郑磊贞
李小平%張曉偉%郭偉劍%鄭磊貞
리소평%장효위%곽위검%정뢰정
胰腺癌%CD44%分子生物学机制%RNA 干扰
胰腺癌%CD44%分子生物學機製%RNA 榦擾
이선암%CD44%분자생물학궤제%RNA 간우
pancreatic cancer%CD44%molecular mechanism%RNAi
目的:利用 RNA 干扰技术沉默人胰腺癌细胞株 PANC -1中 CD44的表达,观察其对肿瘤侵袭性的抑制效果。方法:设计合成有效地干扰 CD44的 shRNA 序列。结果:通过平板克隆形成实验、软琼脂集落形成试验、Transwell 小室侵袭实验发现,胰腺癌细胞株转染干扰 CD44的 shRNA 序列后,其相关的增殖以及侵袭能力明显受抑制。Western Blot 发现随着 CD44的下调,AKT 被逐渐上调,而 p -ERK、p -AKT 却被逐渐下调。结论:靶向 CD44的 shRNA 技术可有效降低人胰腺癌细胞株 PANC -1的侵袭能力,可能的机制与影响其下游的 p -AKT、p -ERK 表达有关。针对 CD44的 RNA 干扰具有潜在的临床价值。
目的:利用 RNA 榦擾技術沉默人胰腺癌細胞株 PANC -1中 CD44的錶達,觀察其對腫瘤侵襲性的抑製效果。方法:設計閤成有效地榦擾 CD44的 shRNA 序列。結果:通過平闆剋隆形成實驗、軟瓊脂集落形成試驗、Transwell 小室侵襲實驗髮現,胰腺癌細胞株轉染榦擾 CD44的 shRNA 序列後,其相關的增殖以及侵襲能力明顯受抑製。Western Blot 髮現隨著 CD44的下調,AKT 被逐漸上調,而 p -ERK、p -AKT 卻被逐漸下調。結論:靶嚮 CD44的 shRNA 技術可有效降低人胰腺癌細胞株 PANC -1的侵襲能力,可能的機製與影響其下遊的 p -AKT、p -ERK 錶達有關。針對 CD44的 RNA 榦擾具有潛在的臨床價值。
목적:이용 RNA 간우기술침묵인이선암세포주 PANC -1중 CD44적표체,관찰기대종류침습성적억제효과。방법:설계합성유효지간우 CD44적 shRNA 서렬。결과:통과평판극륭형성실험、연경지집락형성시험、Transwell 소실침습실험발현,이선암세포주전염간우 CD44적 shRNA 서렬후,기상관적증식이급침습능력명현수억제。Western Blot 발현수착 CD44적하조,AKT 피축점상조,이 p -ERK、p -AKT 각피축점하조。결론:파향 CD44적 shRNA 기술가유효강저인이선암세포주 PANC -1적침습능력,가능적궤제여영향기하유적 p -AKT、p -ERK 표체유관。침대 CD44적 RNA 간우구유잠재적림상개치。
Objective:We investigated the potential functions of shRNA in CD44 targeting in pancreatic cancer cells.Methods:To devise and synthesis of effectively interference of shRNA sequence of CD44,which was transefect-ed to the pancreatic cancer cells.Results:After the transfection,pancreatic cancer cells'proliferation and invasion a-bilities were obviously inhibited by the colony formation assay,soft agar colony formation test,Transwell chamber inva-sion assay.Western Blot showed that p -ERK,p -AKT was reduced and the AKT were gradually raised in protein levels.Conclusion:shRNA targets CD44 in pancreatic cancer cells and suppresses pancreatic cancer cell growth and metastasis in vitro.This project may provide highly effective targeted therapy for pancreatic cancer and provide a new idea and method for targeting CD44.